Rare in 1.4 billion people
Article No 324 26 February 2020 Like many medical institutions around the world this week The Lancet (Haematology) ,an offshoot of…
aHUS genetics- the basics
Article No. 322 21 February 2020 One thing is plainly clear, for most people genetics is a difficult and complex science.…
aHUS- some do some don’t
Article No. 321 20 February 2020 Recalling a couple of questions in the 2017 Rare Diseases Day video about something that…
Spotlight on Ravulizumab 4- side effects
Article No. 320 19 February 2020 Continuing in the series of news blogs about Ravulizumab, which so far has covered…
aHUS trials watch 9
Article No. 318 13 February 2020 The alliance has reported on the development of OMS721 made by Omeros before. It is…
Spotlight on Ravulizumab 3- developments
Article No. 317 6 February 2020 Just a few days ago, Alexion reported on its financial performance for 2019. Its net…
aHUS or TMA syndromes consensus
Article No. 316 1 February 2020 The alliance has featured what are known as aHUS consensus or status publications about the…
Spotlight on Ravulizumab 2- use in specific populations
Article No. 315 30 January 2020 Following on from the first spotlight on ravulizumab article about its dosing (click here to…
aHUS- when PEX is a success
Article No. 314 28 January 2020 One of the interests of the aHUS patient community is whether remission from treatment can continue…
- Go to the previous page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- …
- 23
- Go to the next page